search
Back to results

Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)

Primary Purpose

Head and Neck Carcinoma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dietary intervention
Sponsored by
Sidney Kimmel Cancer Center at Thomas Jefferson University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Head and Neck Carcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH are eligible to participate.
  2. Subjects must be ≥ 18 and ≤ 70 years of age.
  3. KPS > 70
  4. Expected survival > 6 months.
  5. Adequate organ functions (hematological, hepatic, renal function).
  6. Absolute neutrophil count > 1.5 x 109/L, platelet count > 100 x 109/L, hemoglobin > 9 g/L, total bilirubin < 1.25 x the institutional upper limit of normal [ULN], albumin > 2.5 g/dL, aspartate aminotransferase < 45 IU/dL, alanine aminotransferase < 40 IU/dL, alkaline phosphatase ≤ 190 IU/dL and serum creatinine < 1.3 mg/dL and creatinine clearance > 50 mL/min.
  7. Serum potassium and magnesium, and corrected serum calcium within the institution's normal reference range.
  8. Ability to provide written informed consent obtained prior to participation in the study.
  9. Women of childbearing potential (WOCBP) must be willing to use an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized.
  10. Patients' availability to check their weight twice per week, during the study duration.

Exclusion Criteria:

  1. Diabetic patients are eligible but will be excluded if they are taking metformin, insulin or sulfonilureas.
  2. Patients with plasma alanine aminotransferase greater than 40 IU/dL.
  3. Patients with plasma aspartate aminotransferase greater than 45 IU/dL.
  4. Patients with plasma creatinine level greater than 1.3 mg/dL.
  5. Patients with plasma alkaline phosphatase greater than 190 IU/dL.
  6. Patients with plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis.
  7. Patients with history of congestive heart failure.
  8. Patients with myocardial ischemia or peripheral muscle ischemia.
  9. Patients with sepsis or severe infection.
  10. Patients with history of lung disease currently requiring any pharmacologic or supplemental oxygen treatment.
  11. Patients scheduled for definitive HNC cancer surgical resection less than 10 days from enrollment or greater than five weeks from enrollment.
  12. Patients with history of hepatic dysfunction or hepatic disease.
  13. Patients with a history of excessive alcohol intake which is defined in accordance with CDC definitions as more than 1 drink per day for women and more than 2 drinks per day for men. This definition is referring to the amount consumed on any single day and is not intended as an average over several days. A standard drink is equal to 13.7 grams (0.6 ounces) of pure alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey).
  14. Patients with a lower BMI (BMI<18) will be excluded.
  15. Patients with history of known defects in fat metabolism (ie pyruvate carboxylase deficiency, prophyria, fatty acid oxidation defects, primary carnitine deficiencies, organic acidurias, hypoglicemia) will be excluded.
  16. Pregnancy, lactation or inability to use medically acceptable birth control if of childbearing potential.

Sites / Locations

  • Thomas Jefferson University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Low Carbohydrate Diet

Arm Description

Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).

Outcomes

Primary Outcome Measures

Change in TOMM20 expression by IHC
IHC status will be classified as positive or negative pre-and post-treatment. Change in IHC status will be evaluated using McNemar's test for paired dichotomous data.
Change in MCT4 expression in fibroblasts
IHC status will be classified as positive or negative pre-and post-treatment. Change in IHC status will be evaluated using McNemar's test for paired dichotomous data.
Incidence of adverse events, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0

Secondary Outcome Measures

Feasibility of a low-carbohydrate normocaloric diet treatment in HNC patients
Analysis will be descriptive
Change in serum levels of insulin
Change in serum levels of IGF-1
Change in serum levels of IGF-2
Disease-free survival
Estimated using the Kaplan-Meier method.
Distant metastases-free survival
Estimated using the Kaplan-Meier method.
Overall survival
Estimated using the Kaplan-Meier method.

Full Information

First Posted
September 9, 2015
Last Updated
March 15, 2019
Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
search

1. Study Identification

Unique Protocol Identification Number
NCT02555176
Brief Title
Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)
Official Title
A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
December 14, 2016 (Actual)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
October 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This pilot clinical trial studies the effects of a low carbohydrate diet on tumor metabolism in patients with head and neck cancer. A low carbohydrate diet may reduce the metabolic activity of cancer cells and of surrounding supportive tissues. Studying samples of tissue and blood from patients with head and neck cancer in the laboratory before and after a low carbohydrate diet may help determine any changes in tumor metabolism.
Detailed Description
PRIMARY OBJECTIVES: I. Assess the impact of a low-carbohydrate normocaloric diet on transporter of the outer mitochondrial membrane subunit 20 (TOMM20) expression by immunohistochemistry (IHC) in carcinoma cells and the impact of a low-carbohydrate normocaloric diet on monocarboxylate transporter 4 (MCT4) expression in fibroblasts. SECONDARY OBJECTIVES: I. Assess the feasibility of a low-carbohydrate normocaloric diet treatment in head and neck carcinoma (HNC) patients. II. Assess the effect of a low-carbohydrate normocaloric diet on the serum levels of insulin, and insulin growth factor (IGF)-1 and -2. III. Assess the potential impact of a low-carbohydrate normocaloric diet on the following: disease-free survival, distant metastases-free survival, overall survival. IV. To evaluate the utility of cancer-derived exosomes to serve as prognostic biomarkers for real-time monitoring of therapeutic efficacy and identifying early recurrence using longitudinal samples from cancer patients undergoing treatment. OUTLINE: Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment). After completion of study, patients are followed up at 1 month, 3 months, and then every 3 months for 24 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Carcinoma

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low Carbohydrate Diet
Arm Type
Experimental
Arm Description
Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).
Intervention Type
Dietary Supplement
Intervention Name(s)
Dietary intervention
Intervention Description
Follow a low-carbohydrate diet
Primary Outcome Measure Information:
Title
Change in TOMM20 expression by IHC
Description
IHC status will be classified as positive or negative pre-and post-treatment. Change in IHC status will be evaluated using McNemar's test for paired dichotomous data.
Time Frame
Baseline to up to 28 days (day of surgery)
Title
Change in MCT4 expression in fibroblasts
Description
IHC status will be classified as positive or negative pre-and post-treatment. Change in IHC status will be evaluated using McNemar's test for paired dichotomous data.
Time Frame
Baseline to up to 28 days (day of surgery)
Title
Incidence of adverse events, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0
Time Frame
Up to 24 months after surgery
Secondary Outcome Measure Information:
Title
Feasibility of a low-carbohydrate normocaloric diet treatment in HNC patients
Description
Analysis will be descriptive
Time Frame
Up to 28 days
Title
Change in serum levels of insulin
Time Frame
Baseline to up to 24 months
Title
Change in serum levels of IGF-1
Time Frame
Baseline to up to 24 months
Title
Change in serum levels of IGF-2
Time Frame
Baseline to up to 24 months
Title
Disease-free survival
Description
Estimated using the Kaplan-Meier method.
Time Frame
Up to 24 months after surgery
Title
Distant metastases-free survival
Description
Estimated using the Kaplan-Meier method.
Time Frame
Up to 24 months after surgery
Title
Overall survival
Description
Estimated using the Kaplan-Meier method.
Time Frame
Up to 24 months after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH are eligible to participate. Subjects must be ≥ 18 and ≤ 70 years of age. KPS > 70 Expected survival > 6 months. Adequate organ functions (hematological, hepatic, renal function). Absolute neutrophil count > 1.5 x 109/L, platelet count > 100 x 109/L, hemoglobin > 9 g/L, total bilirubin < 1.25 x the institutional upper limit of normal [ULN], albumin > 2.5 g/dL, aspartate aminotransferase < 45 IU/dL, alanine aminotransferase < 40 IU/dL, alkaline phosphatase ≤ 190 IU/dL and serum creatinine < 1.3 mg/dL and creatinine clearance > 50 mL/min. Serum potassium and magnesium, and corrected serum calcium within the institution's normal reference range. Ability to provide written informed consent obtained prior to participation in the study. Women of childbearing potential (WOCBP) must be willing to use an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. Patients' availability to check their weight twice per week, during the study duration. Exclusion Criteria: Diabetic patients are eligible but will be excluded if they are taking metformin, insulin or sulfonilureas. Patients with plasma alanine aminotransferase greater than 40 IU/dL. Patients with plasma aspartate aminotransferase greater than 45 IU/dL. Patients with plasma creatinine level greater than 1.3 mg/dL. Patients with plasma alkaline phosphatase greater than 190 IU/dL. Patients with plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis. Patients with history of congestive heart failure. Patients with myocardial ischemia or peripheral muscle ischemia. Patients with sepsis or severe infection. Patients with history of lung disease currently requiring any pharmacologic or supplemental oxygen treatment. Patients scheduled for definitive HNC cancer surgical resection less than 10 days from enrollment or greater than five weeks from enrollment. Patients with history of hepatic dysfunction or hepatic disease. Patients with a history of excessive alcohol intake which is defined in accordance with CDC definitions as more than 1 drink per day for women and more than 2 drinks per day for men. This definition is referring to the amount consumed on any single day and is not intended as an average over several days. A standard drink is equal to 13.7 grams (0.6 ounces) of pure alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). Patients with a lower BMI (BMI<18) will be excluded. Patients with history of known defects in fat metabolism (ie pyruvate carboxylase deficiency, prophyria, fatty acid oxidation defects, primary carnitine deficiencies, organic acidurias, hypoglicemia) will be excluded. Pregnancy, lactation or inability to use medically acceptable birth control if of childbearing potential.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Curry, MD
Organizational Affiliation
Thomas Jefferson University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States

12. IPD Sharing Statement

Links:
URL
http://hospitals.jefferson.edu/
Description
Jefferson University Hospitals

Learn more about this trial

Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)

We'll reach out to this number within 24 hrs